PE20040808A1 - Derivados de urea ciclica como inhibidores de quinasas - Google Patents
Derivados de urea ciclica como inhibidores de quinasasInfo
- Publication number
- PE20040808A1 PE20040808A1 PE2004000090A PE2004000090A PE20040808A1 PE 20040808 A1 PE20040808 A1 PE 20040808A1 PE 2004000090 A PE2004000090 A PE 2004000090A PE 2004000090 A PE2004000090 A PE 2004000090A PE 20040808 A1 PE20040808 A1 PE 20040808A1
- Authority
- PE
- Peru
- Prior art keywords
- imidazolidine
- trifluoromethanosulfonyl
- ilmethyl
- trifluoroacetate
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE P ES 0 A 2; R Y R1 SON O, NH; R2 Y R3 SON HIDROGENO, ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, ARILO Y HETEROARILO EVENTUALMENTE SUBSTITUIDO O R2 Y R3 FORMAN JUNTOS CON EL CARBONO A LOS CUALES ESTAN UNIDOS UN RADICAL CARBOCICLICO O HETEROCICLICO, ENTRE OTROS; A1 ES UN ENLACE SENCILLO, ALQUILO, ALQUENILO, ALQUINILO; Y E Y1 SON H, OCF3, S(O)nCF3, O-CF2-CHF2, -O-CHF2, ENTRE OTROS; Y E Y1 SON H, HALO, OH, NR5R6 ENTRE OTROS; R5 Y R6 SON HIDROGENO, ALQUILO, ALQUENILO, CICLOALQUILO, ENTRE OTROS O R5 Y R6 FORMAN CON EL N AL CUAL ESTAN UNIDOS UN RADICAL HETEROCICLICO, ENTRE OTROS; A2 REPRESENTAN LOS VALORES DE A1 Y CO Y S02; B2 ES HETEROCICLICO SATURADO O NO SATURADO CONTENIENDO UNO A VARIOS HETEROATOMOS, ENTRE OTROS; Y2 ES H, HALOGENO, HIDROXILO, ALQUILO, ALCOXI, ENTRE OTROS. n ES 0 A 2. SON COMPUESTOS PREFERIDOS TRIFLUOROACETATO DE (S)-5-METIL-1-QUINOLIN-4-ILMETIL-3-(4-TRIFLUOROMETANOSULFONIL-FENIL)-IMIDAZOLIDINO-2,4-DIONA, TRIFLUOROACETATO DE (S)-5-METIL-1-PIRIDIN-4-ILMETIL-3-(4-TRIFLUOROMETANOSULFONIL-FENIL)- IMIDAZOLIDINO-2,4-DIONA, TRIFLUOROACETATO DE (S)-5-METIL-1-QUINOLIN-4-ILMETIL-3-(4-TRIFLUOROMETANOSULFONIL-FENIL) IMIDAZOLIDINO-2,4-DIONA, TRIFLUOROACETATO DE (R)-4-METIL-3-QUINOLIN-4-ILMETIL-3-(4-TRIFLUOROMETANOSULFONIL-FENIL)-IMIDAZOLIDINO-2-ONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE QUINASAS (GRUPO FAK) UTILES PARA TRATAMIENTOS EN ONCOLOGIA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0301098A FR2850652B1 (fr) | 2003-01-31 | 2003-01-31 | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20040808A1 true PE20040808A1 (es) | 2004-12-31 |
Family
ID=32696243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004000090A PE20040808A1 (es) | 2003-01-31 | 2004-01-22 | Derivados de urea ciclica como inhibidores de quinasas |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1599464B1 (es) |
JP (1) | JP4604020B2 (es) |
KR (1) | KR20050098286A (es) |
CN (1) | CN1768054A (es) |
AR (1) | AR042936A1 (es) |
AT (1) | ATE482207T1 (es) |
AU (1) | AU2004209319A1 (es) |
BR (1) | BRPI0407091A (es) |
CA (1) | CA2513631A1 (es) |
DE (1) | DE602004029236D1 (es) |
FR (1) | FR2850652B1 (es) |
HR (1) | HRP20050679A2 (es) |
MA (1) | MA27651A1 (es) |
ME (1) | MEP22608A (es) |
MX (1) | MXPA05007407A (es) |
NO (1) | NO20054006L (es) |
NZ (1) | NZ541270A (es) |
PE (1) | PE20040808A1 (es) |
PL (1) | PL377811A1 (es) |
RS (1) | RS20050657A (es) |
RU (1) | RU2341523C2 (es) |
TW (1) | TW200505898A (es) |
WO (1) | WO2004070050A2 (es) |
ZA (1) | ZA200505934B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005077344A2 (en) | 2003-08-29 | 2005-08-25 | The Brigham And Women's Hospital, Inc. | Hydantoin derivatives as inhibitors of cellular necrosis |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
AU2004305075A1 (en) | 2003-12-19 | 2005-07-07 | The Regents Of The University Of California | Methods and materials for assessing prostate cancer therapies |
NZ550102A (en) | 2004-02-24 | 2010-10-29 | Univ California | Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives) |
EP1621535A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
EP1621536A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
KR101332924B1 (ko) | 2005-05-13 | 2013-11-26 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴히단토인 화합물 |
US7709516B2 (en) * | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
FR2896504B1 (fr) * | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
FR2896503B1 (fr) * | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
HUE027894T2 (en) | 2006-03-27 | 2016-11-28 | Univ California | An androgen receptor modulator for the treatment of prostate cancer and androgen receptor related diseases |
SG10201408699TA (en) | 2006-03-29 | 2015-02-27 | Univ California | Diarylthiohydantoin compounds |
RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
JP2010512389A (ja) | 2006-12-12 | 2010-04-22 | シェーリング コーポレイション | アスパルチルプロテアーゼ阻害剤 |
EP2620432A3 (en) | 2007-10-26 | 2013-12-18 | The Regents Of the University of California | Diarylhydantoin compounds |
AU2009329879A1 (en) | 2008-12-23 | 2011-08-11 | President And Fellows Of Harvard College | Small molecule inhibitors of necroptosis |
EP3124481B1 (en) | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
EP2655428B1 (en) * | 2010-12-21 | 2022-09-14 | Cytec Technology Corp. | Microdispersions of hydroxamated polymers and methods of making and using them |
US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
SG10201912719TA (en) | 2012-09-26 | 2020-02-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
GB201312492D0 (en) * | 2013-07-12 | 2013-08-28 | Syngenta Ltd | Herbicidal compounds |
BR112016016289B1 (pt) | 2014-01-14 | 2023-02-07 | Takeda Pharmaceutical Company Limited | Heteroaris e usos dos mesmos |
WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
EP3229807A4 (en) | 2014-12-11 | 2018-10-17 | President and Fellows of Harvard College | Inhibitors of cellular necrosis and related methods |
TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
CN107619388A (zh) * | 2016-07-13 | 2018-01-23 | 南京天印健华医药科技有限公司 | 作为fgfr抑制剂的杂环化合物 |
CN109641871B (zh) * | 2016-07-20 | 2021-10-22 | 诺华股份有限公司 | 氨基吡啶衍生物及其作为选择性alk-2抑制剂的用途 |
AU2018351714A1 (en) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
CN111542513A (zh) * | 2017-10-31 | 2020-08-14 | 佩勒梅德有限公司 | 用于预防或治疗急性髓性白血病或转移性乳腺癌的药物组合物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2329276A1 (fr) * | 1975-10-29 | 1977-05-27 | Roussel Uclaf | Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant |
DE4228717A1 (de) * | 1992-08-28 | 1994-03-03 | Cassella Ag | Imidazolidin-Derivate |
DE19540027A1 (de) * | 1995-10-27 | 1997-04-30 | Gruenenthal Gmbh | Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe |
DK0966447T3 (da) * | 1997-03-03 | 2003-06-23 | Boehringer Ingelheim Pharma | Anvendelige små molekyler til behandling af betændelsessygdomme |
DE19732928C2 (de) * | 1997-07-31 | 2000-05-18 | Gruenenthal Gmbh | Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel |
FR2796945B1 (fr) * | 1999-07-30 | 2002-06-28 | Sod Conseils Rech Applic | Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments |
CN1209358C (zh) * | 2000-05-31 | 2005-07-06 | 田边制药株式会社 | αLβ2介导细胞粘连的抑制剂 |
CA2486090C (en) * | 2002-05-16 | 2011-07-05 | Bayer Cropscience Gmbh | Pyridine carboxamide derivatives and their use as pesticides |
-
2003
- 2003-01-31 FR FR0301098A patent/FR2850652B1/fr not_active Expired - Fee Related
-
2004
- 2004-01-22 PE PE2004000090A patent/PE20040808A1/es not_active Application Discontinuation
- 2004-01-27 AR ARP040100233A patent/AR042936A1/es unknown
- 2004-01-28 CN CNA2004800088356A patent/CN1768054A/zh active Pending
- 2004-01-28 AU AU2004209319A patent/AU2004209319A1/en not_active Abandoned
- 2004-01-28 WO PCT/FR2004/000188 patent/WO2004070050A2/fr active Application Filing
- 2004-01-28 PL PL377811A patent/PL377811A1/pl not_active Application Discontinuation
- 2004-01-28 MX MXPA05007407A patent/MXPA05007407A/es active IP Right Grant
- 2004-01-28 BR BR0407091-7A patent/BRPI0407091A/pt not_active IP Right Cessation
- 2004-01-28 DE DE602004029236T patent/DE602004029236D1/de not_active Expired - Lifetime
- 2004-01-28 ME MEP-226/08A patent/MEP22608A/xx unknown
- 2004-01-28 JP JP2006502123A patent/JP4604020B2/ja not_active Expired - Fee Related
- 2004-01-28 EP EP04705838A patent/EP1599464B1/fr not_active Expired - Lifetime
- 2004-01-28 RU RU2005127335/04A patent/RU2341523C2/ru not_active IP Right Cessation
- 2004-01-28 RS YUP-2005/0657A patent/RS20050657A/sr unknown
- 2004-01-28 AT AT04705838T patent/ATE482207T1/de not_active IP Right Cessation
- 2004-01-28 CA CA002513631A patent/CA2513631A1/fr not_active Abandoned
- 2004-01-28 KR KR1020057014096A patent/KR20050098286A/ko not_active Application Discontinuation
- 2004-01-28 NZ NZ541270A patent/NZ541270A/en unknown
- 2004-01-30 TW TW093102064A patent/TW200505898A/zh unknown
-
2005
- 2005-07-22 ZA ZA200505934A patent/ZA200505934B/en unknown
- 2005-07-29 HR HR20050679A patent/HRP20050679A2/xx not_active Application Discontinuation
- 2005-07-29 MA MA28417A patent/MA27651A1/fr unknown
- 2005-08-29 NO NO20054006A patent/NO20054006L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2341523C2 (ru) | 2008-12-20 |
HRP20050679A2 (en) | 2006-12-31 |
RU2005127335A (ru) | 2006-09-10 |
BRPI0407091A (pt) | 2006-01-24 |
MA27651A1 (fr) | 2005-12-01 |
CA2513631A1 (fr) | 2004-08-19 |
ATE482207T1 (de) | 2010-10-15 |
WO2004070050A2 (fr) | 2004-08-19 |
FR2850652A1 (fr) | 2004-08-06 |
ZA200505934B (en) | 2007-06-27 |
TW200505898A (en) | 2005-02-16 |
EP1599464A2 (fr) | 2005-11-30 |
PL377811A1 (pl) | 2006-02-20 |
AR042936A1 (es) | 2005-07-06 |
JP4604020B2 (ja) | 2010-12-22 |
CN1768054A (zh) | 2006-05-03 |
JP2006517569A (ja) | 2006-07-27 |
MEP22608A (en) | 2010-06-10 |
AU2004209319A1 (en) | 2004-08-19 |
FR2850652B1 (fr) | 2008-05-30 |
KR20050098286A (ko) | 2005-10-11 |
RS20050657A (en) | 2007-06-04 |
EP1599464B1 (fr) | 2010-09-22 |
NO20054006L (no) | 2005-10-13 |
MXPA05007407A (es) | 2005-09-12 |
NZ541270A (en) | 2008-11-28 |
NO20054006D0 (no) | 2005-08-29 |
DE602004029236D1 (de) | 2010-11-04 |
WO2004070050A3 (fr) | 2005-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20040808A1 (es) | Derivados de urea ciclica como inhibidores de quinasas | |
PE20060556A1 (es) | Derivados de urea ciclicos sustituidos con heterociclo como inhibidores de quinasa | |
AR052559A1 (es) | Derivados de pirazol para inhibir cdk's y gsk's | |
PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
AR055360A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
PE20060383A1 (es) | Nuevos derivados amino de urea ciclicos como inhibidores de quinasa | |
NO20073729L (no) | Heterocykliske forbindelser som CCR2B-antagonister | |
PE20040189A1 (es) | Pirimidina y piridina biciclicos como inhibidores de p38 quinasa | |
UA81468C2 (en) | Heteroarylcarbamoylbenzene derivatives | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
BR0209334A (pt) | Aminas n-aroil cìclicas | |
PE20090709A1 (es) | Compuestos heterociclico de 5 miembros | |
PE20040934A1 (es) | Derivados de pirimidina como inhibidores selectivos de tirosina quinasas | |
ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
ECSP066298A (es) | Compuestos 1h-pirazol 3,4-disustituidos y su uso como moduladores de quinasas dependientes de ciclina (cdk) y quinasa-3 de sintasa de glicógeno (gsk-3) | |
PE20060334A1 (es) | Derivados de piridina como antagonistas del receptor a2b de adenosina | |
AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
PE20090895A1 (es) | Derivados de triazol como inhibidores de la jak quinasa | |
ES2391373T3 (es) | Derivados de quinoleína como inhibidores de la cinasa AXL | |
DE60007329D1 (de) | N-heterozyklische derivate als nos inhibitoren | |
PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
PE20040156A1 (es) | 2-heteroaril-pirimidinas como inhibidores de quinasa dependiente de ciclina | |
NO20050429L (no) | Substituert kinolin-CCR5-reseptorantagonister | |
PE20070585A1 (es) | Derivados de sulfonamida como activadores de glucoquinasa | |
CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal | ||
AE | Restoration of lapsed or forfeited application | ||
FG | Grant, registration | ||
FD | Application declared void or lapsed |